A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

Nearly nine million people in the U.S. have an inflammatory skin condition called plaque psoriasis. We're raising awareness ...

The researchers note that roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which targets inflammatory pathways central ...

Some medicines used for heart problems, like beta-blockers, ACE inhibitors, and calcium channel blockers, have been known to sometimes start new cases of psoriasis or make it worse in some people.

Inspired by feedback from the hidradenitis suppurativa (HS) community, the campaign aims to raise awareness of BIMZELX and features a broad range of ...

VYNE Therapeutics Inc. (NASDAQ:VYNE) is among the fundamentally strong penny stocks to invest in. Analysts at H.C. Wainwright ...

Autoimmune diseases like lupus rheumatoid arthritis and psoriasis don’t just affect joints or skin they can silently damage ...